-- British Columbia Also Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions -- MISSISSAUGA, ON, March 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective March 21, 2017, British Columbia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C ...
-- Quebec Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions -- MISSISSAUGA, ON, March 20, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) commends the continued leadership of Quebec in the treatment of hepatitis C with the listing of EPCLUSA™ (sofosbuvir/velpatasvir) tablets effective on March 22, 2017. EPCLUSA is the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with g...
The eradication of hepatitis C may be on the horizon. New, expensive drugs approved by the Ontario government mean new hope for those suffering from liver-destroying hepatitis C, a potentially fatal virus that many people don’t even know they have. The Ontario government has added six new hepatitis drugs to its Ontario Public Drug Programs that will help cure the 40 per cent of hepatitis sufferers who formerly were unable to access treatment. “It’s a v
Friday, February 24, 2017 News Recap Better Public Access to New HepC Meds Announced in Canada This week the pan-Canadian Pharmaceutical Alliance (pCPA), on behalf of participating federal, provincial and territorial public drug plans, concluded successful negotiations with three drug manufacturers to help jurisdictions expand access to publicly funded medications for the treatment of chronic hepatitis C. What this Means: Immediately following th...
Ontario Also Broadens Access for Patients with Less Advanced Disease with Co-Factors —MISSISSAUGA, ON, Feb. 22, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective February 28th, 2017, Ontario will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. This listing
Epclusa™, a Direct-Acting-Antiviral combo for ALL GENOTYPES of Chronic Hepatitis C, received approval from CADTH on October 28, 2016. This combo of (generics) sofosbuvir and velpatasvir, from Gilead Sciences, was recommended by CADTH's Canadian Drug Expert Committtee (CDEC) for reimbursement by provincial and territorial PharmaCares... "if the following CRITERION and CONDITION are met: (1) CONDITION: "Reduce the price." CDEC noted that the cost of t
New Health Canada approved drug costs more than $700 a pill. The list price in Canada is set at $60,000 for a 12-week course EPCLUSA TORONTO - Health Canada has approved a drug being touted as a cure for hepatitis C, a disease believed to have infected hundreds of thousands of Canadians, many of whom are unaware they harbour the virus. The drug, sold under the brand name Epclusa, is a once-daily pill taken for 12 weeks that can rid the
Though Health Canada has now approved what is considered a miracle drug for hepatitis C treatment, there remain significant barriers to receiving timely treatment. The drug, Epclusa, was approved earlier this week by the federal health agency to much fanfare from doctors across the country. The drug, which has shown to eliminate all strains of hepatitis C from the body, is to be taken once daily for 12 weeks, which according to The Canadian Press comes at
WASHINGTON: A latest breakthrough treatment for the deadly Hepatitis C virus could soon be available in India as 11 Indian firms have been given licenses by its American manufacturer following an approval from US authorities. The drug called Epclusa which is developed to treat all genotypes of the Hepatitis C virus by Gilead Sciences in its latest breakthrough treatment was last week approved by the US Food and Drug Administration (FDA). The deadly Hep
Gilead's pan-genotypic hepatitis C virus combo, Epclusa, could significantly boost the company's sales by filling some important niches. Antiviral champ Gilead Sciences recently earned FDA approval for another hepatitis C virus (HCV) combination treatment, Epclusa. Epclusa is poised to boost Gilead's numbers by filling an important niche that has been somewhat overlooked, and Bristol-Myers Squibb is about to lose hundreds of millions annually in the